Subject(s)
Hospice Care , Patient Education as Topic , Resuscitation Orders , Hospice Care/psychology , HumansSubject(s)
Carcinoma, Bronchogenic/therapy , Carcinoma, Small Cell/therapy , Lung Neoplasms/therapy , Antineoplastic Agents/therapeutic use , Carcinoma, Bronchogenic/drug therapy , Carcinoma, Bronchogenic/surgery , Carcinoma, Small Cell/drug therapy , Carcinoma, Small Cell/surgery , Humans , Immunotherapy , Lung Neoplasms/drug therapy , Lung Neoplasms/surgeryABSTRACT
The epipodophyllotoxin derivative VP 16--213 (NSC 141540) was studied by the Cancer and Leukemia Group B in a broad phase II trial at three dose levels: 60 mg/m2, 90 mg/m2, and 135 mg/m2 I.V. twice weekly. No correlation between dose of VP 16--213 and response frequency in a particular disease category could be demonstrated. Of the 382 patients, 8% obtained a complete (CR) or partial remission (PR), 8% showed improvement, and 14% had stable disease. By tumor type the best responses were obtained in lymphomas (8/31 CR + PR), uterus (2/9), prostate (1/5), rhabdomyosarcoma (2/6), neuroblastoma (2/4), colon/rectum (5/81), other gastrointestinal (4/32). In lung tumors, 4/80 patients obtained CR or PR. VP 16--213 has definite antineoplastic activity but the response frequency with the twice weekly schedule may be lower than that reported with other schedules.
Subject(s)
Etoposide/administration & dosage , Neoplasms/drug therapy , Podophyllotoxin/analogs & derivatives , Adult , Bone Marrow/drug effects , Child , Clinical Trials as Topic , Drug Administration Schedule , Etoposide/adverse effects , Female , Humans , Injections, Intravenous , Male , Remission, SpontaneousSubject(s)
Ataxia/chemically induced , Fluorouracil/toxicity , Mitomycins/toxicity , Adenocarcinoma/drug therapy , Aged , Blood-Brain Barrier , Cerebellar Ataxia/chemically induced , Colonic Neoplasms/drug therapy , Fluorouracil/therapeutic use , Humans , Male , Mitomycins/therapeutic use , Neoplasm MetastasisSubject(s)
Anemia, Pernicious/complications , Leukemia, Myeloid, Acute/etiology , Aged , Humans , MaleSubject(s)
Neoplasms , Aged , Analgesics/therapeutic use , Antineoplastic Agents/therapeutic use , Breast Neoplasms/diagnosis , Breast Neoplasms/drug therapy , Breast Neoplasms/surgery , Colonic Neoplasms/diagnosis , Colonic Neoplasms/mortality , Colonic Neoplasms/surgery , Diethylstilbestrol/therapeutic use , Female , Humans , Lung Neoplasms/diagnosis , Lung Neoplasms/therapy , Male , Neoplasms/diagnosis , Neoplasms/therapy , Prostatic Neoplasms/diagnosis , Prostatic Neoplasms/therapy , Rectal Neoplasms/diagnosis , Rectal Neoplasms/mortality , Uterine Neoplasms/diagnosis , Uterine Neoplasms/therapyABSTRACT
Twenty-four patients with non-Hodgkin's lymphoma and CNS involvement are presented. There were 7 cases with diffuse histiocytic lymphoma (HL), 9 with diffuse poorly differentiated lymphocytic lymphoma (PDLL-D), of whom 6 patients were in leukemic conversion, 5 patients with nodular poorly differentiated lymphocytic lymphoma (PDLL-N), and 3 cases with undifferentiated lymphoma (UL). CNS complications were noted only in Stage IV lymphoma; the prognosis was generally poor. Histiocytic lymphoma was associated with widespread parenchymatous infiltration, whereas PDLL was usually associated with leptomeningeal seeding. The clinical course and the neuropathologic findings are discussed.
